Literature DB >> 6214993

Selective inhibition of functional lymphocyte subpopulations by ribavirin.

C N Powers, D L Peavy, V Knight.   

Abstract

The present studies were designed to examine the effects of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), a broad-spectrum antiviral agent, on the generation of murine antibody responses in vitro. Whereas primary and secondary sheep erythrocyte-specific, plaque-forming cell responses by normal murine spleen cells were enhanced by low concentrations of ribavirin (1 microgram per culture), they were strongly inhibited by higher concentrations of ribavirin (5 to 10 micrograms per culture). Both phenomena occurred with the greatest magnitude when spleen cells were exposed to ribavirin 48 to 72 h after culture initiation. Enhancement appeared to result from selective interference with suppressor T cells, since ribavirin failed to augment lipopolysaccharide-specific plaque-forming cell responses in T cell-depleted spleen cell cultures but inhibited concanavalin A-induced lymphocyte proliferation and suppressor T cell generation in cultures of normal spleen cells. The immunosuppressive properties of ribavirin were mediated by a direct antiproliferative effect and, at higher concentrations, a cytotoxic effect for B lymphocytes, since the drug inhibited plaque-forming cell responses in T cell-depleted spleen cell cultures, suppressed lipopolysaccharide-induced lymphocyte proliferation and reduced viable spleen cell recoveries.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214993      PMCID: PMC183682          DOI: 10.1128/AAC.22.1.108

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells.

Authors:  E M Scholar; P Calabresi
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

2.  A requirement for two cell types for antibody formation in vitro.

Authors:  D E Mosier
Journal:  Science       Date:  1967-12-22       Impact factor: 47.728

3.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

4.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

5.  Biological expressions of lymphocyte activation. II. Generation of a population of thymus-derived suppressor lymphocytes.

Authors:  R R Rich; C W Pierce
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

6.  Inhibitory and stimulatory effects of concanavalin A on the response of mouse spleen cell suspensions to antigen. II. Evidence for separate stimulatory and inhibitory cells.

Authors:  R W Dutton
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

7.  Cell interactions in the immune response in vitro. II. The requirement for macrophages in lymphoid cell collaboration.

Authors:  M Feldmann
Journal:  J Exp Med       Date:  1972-05-01       Impact factor: 14.307

8.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

9.  Immune responses in vitro. I. Cellular requirements for the immune response by nonprimed and primed spleen cells in vitro.

Authors:  C W Pierce
Journal:  J Exp Med       Date:  1969-08-01       Impact factor: 14.307

10.  Inhibitory and stimulatory effects of concanavalin A on the response of mouse spleen cell suspensions to antigen. I. Characterization of the inhibitory cell activity.

Authors:  R W Dutton
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 3.  Detection, pathogenesis, and therapy of respiratory syncytial virus infections.

Authors:  R C Welliver
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 4.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

5.  Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.

Authors:  E Connor; S Morrison; J Lane; J Oleske; R L Sonke; J Connor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 6.  Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function.

Authors:  Richard E Kast
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

7.  Determining Ribavirin's mechanism of action against Lassa virus infection.

Authors:  Paola Carrillo-Bustamante; Thi Huyen Tram Nguyen; Lisa Oestereich; Stephan Günther; Jeremie Guedj; Frederik Graw
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 8.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.